发明授权
US08158644B2 Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
有权
含有利福昔明的多形态α，bgr和γ的药物组合物
- 专利标题： Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
- 专利标题（中）： 含有利福昔明的多形态α，bgr和γ的药物组合物
-
申请号： US13041347申请日： 2011-03-04
-
公开(公告)号： US08158644B2公开(公告)日： 2012-04-17
- 发明人: Giuseppe Claudio Viscomi , Manuela Campana , Dario Braga , Donatella Confortini , Vincenzo Cannata , Paolo Righi , Goffredo Rosini
- 申请人： Giuseppe Claudio Viscomi , Manuela Campana , Dario Braga , Donatella Confortini , Vincenzo Cannata , Paolo Righi , Goffredo Rosini
- 申请人地址： IT Bologna
- 专利权人： Alfa Wassermann, S.p.A.
- 当前专利权人： Alfa Wassermann, S.p.A.
- 当前专利权人地址： IT Bologna
- 代理机构： TechLaw LLP
- 代理商 Sam K. Tahmassebi
- 优先权： ITM12003A002144 20031107
- 主分类号： A61K31/395
- IPC分类号： A61K31/395
摘要：
Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin α and rifaximin β, and a poorly crystalline form referred to as rifaximin γ, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.